The significance and pathogenic consequences of proteotoxicity and proteinopathy in failing hearts have received recent clinical notice. Accumulation of defective proteins and their aggregation impair proteostasis and lead to pathological consequences in cardiomyocytes. A homeostatic balance (proteostasis) between synthesis and degradation of defective proteins is crucial for the dynamically active cardiomyocytes. Mounting evidence indicates that a majority of protein aggregation cardiomyopathies (PAC) caused by mutations in cytoskeletal proteins or chaperones involve pre-amyloid aggregates, oxidative stress, mitochondrial dysfunction and apoptotic death of cardiomyocytes. We now demonstrate that constitutive activation of nuclear erythroid-2 like factor-2 (Nrf2) signaling is a potential mechanism for Reductive Stress (RS) and PAC in these pathogenic processes. Our findings pinpoint RS as the metabolic insult responsible for pathogenesis in human cardiac disease. Our long-term goal is to investigate the molecular mechanisms for RS mediated proteotoxic cardiac disease and explore relevant therapeutic interventions. We hypothesize that abnormal increases in intracellular reducing power contributes to RS, which will cause proteotoxic cardiac remodeling and dysfunction through impaired protein quality control mechanisms. Accordingly, we propose the following aims: (1) To determine whether chronic reductive stress (CRS) is sufficient to cause cardiac hypertrophy and pathological remodeling, (2) To determine whether CRS impairs endoplasmic reticulum (ER) and ubiquitin- proteasome function to promote proteotoxicity and protein aggregation and (3) To determine whether preventing RS or preserving ER function rescues the CaNrf2-TG mice from proteotoxic cardiac remodeling and dysfunction. To study these aims, we have established mouse models for RS by constitutively activating Nrf2 (CaNrf2) in the heart [CaNrf2-TG or Keap1-/-:aMHC-Cre-TG (cardiomyocyte-specific constitutive activation of Nrf2 signaling)]. First, we will determine the effects of RS on cardiac function, structural remodeling and stress- induced cardiac hypertrophy in mice with trans-aortic constriction. Next, we will study the effect of RS on redox potential of ER and investigate the mechanisms associated with ER stress and unfolded protein response pathways in the CaNrf2-TG or Keap1-/-:aMHC-CreTG mice with proteotoxic cardiac disease. Then, we will use pharmacological approaches to prevent RS or ER stress to rescue the proteotoxic cardiac disease. Alternatively, we will use genetic approaches to knock down Nrf2 to prevent RS and resultant proteotoxicity. A team of scientists and physicians with relevant experience in cardiac physiology, cardiac imaging, free-radical chemistry, biochemistry, molecular biology and gene therapy will be involved in this project. The proposal also includes a strong plan for educating the next generation (undergraduates and postgraduates) with cutting-edge research. The overall outcome of this study will yield new knowledge on RS and proteotoxic effects in the heart, which will likely enhance therapeutic applications in human patients in the next 5-6 years.

Public Health Relevance

Accumulation of defective proteins and their aggregation impairs the protein quality and induces pathological enlargement (hypertrophy) of cardiac cells, which results in cardiac failure. Reductive stress (abnormal increase in reducing compounds) leads to dysfunction of the endoplasmic reticulum (a cellular component crucial for the synthesis and folding of proteins) and proteotoxicity. In our laboratory, we have generated new animal models with heart-specific reductive stress, and using these exclusive mouse models, we will study the pathways for cardiac remodeling and this will open up new areas of research to understand cardiovascular diseases in humans.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL118067-03
Application #
8910779
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Schwartz, Lisa
Project Start
2013-07-29
Project End
2018-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
3
Fiscal Year
2015
Total Cost
$362,750
Indirect Cost
$110,612
Name
University of Alabama Birmingham
Department
Pathology
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Brewer, Rachel A; Collins, Helen E; Berry, Ryan D et al. (2018) Temporal partitioning of adaptive responses of the murine heart to fasting. Life Sci 197:30-39
Bolus, Daniel J; Shanmugam, Gobinath; Narasimhan, Madhusudhanan et al. (2018) Recurrent heat shock impairs the proliferation and differentiation of C2C12 myoblasts. Cell Stress Chaperones 23:399-410
Quiles, Justin M; Narasimhan, Madhusudhanan; Shanmugam, Gobinath et al. (2017) Differential regulation of miRNA and mRNA expression in the myocardium of Nrf2 knockout mice. BMC Genomics 18:509
Shanmugam, Gobinath; Narasimhan, Madhusudhanan; Conley, Robbie L et al. (2017) Chronic Endurance Exercise Impairs Cardiac Structure and Function in Middle-Aged Mice with Impaired Nrf2 Signaling. Front Physiol 8:268
McGinnis, Graham R; Tang, Yawen; Brewer, Rachel A et al. (2017) Genetic disruption of the cardiomyocyte circadian clock differentially influences insulin-mediated processes in the heart. J Mol Cell Cardiol 110:80-95
Shanmugam, Gobinath; Narasimhan, Madhusudhanan; Tamowski, Susan et al. (2017) Constitutive activation of Nrf2 induces a stable reductive state in the mouse myocardium. Redox Biol 12:937-945
Narasimhan, Madhusudhanan; Rajasekaran, Namakkal-Soorappan (2017) Cardiac Aging - Benefits of Exercise, Nrf2 Activation and Antioxidant Signaling. Adv Exp Med Biol 999:231-255
Quiles, Justin M; Narasimhan, Madhusudhanan; Mosbruger, Timothy et al. (2017) Identification of transcriptome signature for myocardial reductive stress. Redox Biol 13:568-580
Shelar, Sandeep Balu; Narasimhan, Madhusudhanan; Shanmugam, Gobinath et al. (2016) Disruption of nuclear factor (erythroid-derived-2)-like 2 antioxidant signaling: a mechanism for impaired activation of stem cells and delayed regeneration of skeletal muscle. FASEB J 30:1865-79
Narasimhan, Madhusudhanan; Rajasekaran, Namakkal S (2016) Exercise, Nrf2 and Antioxidant Signaling in Cardiac Aging. Front Physiol 7:241

Showing the most recent 10 out of 21 publications